Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W M Johnson

Showing results (151-160 of 218) with videos related to

Pageof 22
Sort By:
Chemotherapy|August 22, 2012
A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancerSimon J Crabb, Jennifer Bradbury, Luke Nolan, et al.
Journal of the National Cancer Institute|September 19, 2002
The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosisUrszula Bugajska, Nikolaos T Georgopoulos, Jennifer Southgate, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 27, 2014
Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunizationJane E Willoughby, Jonathan P Kerr, Anne Rogel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 18, 2009
Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519)W S Owadally, M R Sydes, J A Radford, et al.
Oncogene|September 20, 2006
Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytesF Habens, A S Lapham, C L Dallman, et al.
Insect Biochemistry and Molecular Biology|May 23, 2007
Ligand binding by recombinant domains from insect ecdysone receptorsL D Graham, W M Johnson, A Pawlak-Skrzecz, et al.
Cancer Immunology, Immunotherapy : CII|April 2, 2013
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbsAnn L White, H T Claude Chan, Ruth R French, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2018
Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?Ronald Boellaard, Carsten Kobe, Josée M Zijlstra, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2025
PET-Based Risk Stratification in Primary Mediastinal B-Cell Lymphoma: A Comparative Analysis of Different Segmentation Methods in the IELSG37 Trial Patient CohortLuca Ceriani, Lisa Milan, Maria Cristina Pirosa, et al.
Cancer Immunology, Immunotherapy : CII|April 23, 2013
Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cellsBen C King, Angela D Hamblin, Philip M Savage, et al.
Pageof 22

Showing results (151-160 of 218) with videos related to

Sort By:
Pageof 22
Chemotherapy|August 22, 2012
A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancerSimon J Crabb, Jennifer Bradbury, Luke Nolan, et al.
Journal of the National Cancer Institute|September 19, 2002
The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosisUrszula Bugajska, Nikolaos T Georgopoulos, Jennifer Southgate, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 27, 2014
Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunizationJane E Willoughby, Jonathan P Kerr, Anne Rogel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 18, 2009
Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519)W S Owadally, M R Sydes, J A Radford, et al.
Oncogene|September 20, 2006
Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytesF Habens, A S Lapham, C L Dallman, et al.
Insect Biochemistry and Molecular Biology|May 23, 2007
Ligand binding by recombinant domains from insect ecdysone receptorsL D Graham, W M Johnson, A Pawlak-Skrzecz, et al.
Cancer Immunology, Immunotherapy : CII|April 2, 2013
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbsAnn L White, H T Claude Chan, Ruth R French, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2018
Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?Ronald Boellaard, Carsten Kobe, Josée M Zijlstra, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 17, 2025
PET-Based Risk Stratification in Primary Mediastinal B-Cell Lymphoma: A Comparative Analysis of Different Segmentation Methods in the IELSG37 Trial Patient CohortLuca Ceriani, Lisa Milan, Maria Cristina Pirosa, et al.
Cancer Immunology, Immunotherapy : CII|April 23, 2013
Antibody-peptide-MHC fusion conjugates target non-cognate T cells to kill tumour cellsBen C King, Angela D Hamblin, Philip M Savage, et al.
Pageof 22